9 active not recruiting, 9 terminated, 4 recruiting, 3 completed. 12 Phase 1, 10 Phase 2, 1 Early Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Active not recruiting 4, Recruiting 4, Terminated 4 |
| Phase 2 | 10 | Terminated 5, Active not recruiting 3, Completed 2 |
| Early Phase 1 | 1 | Completed 1 |
| Not applicable | 1 | Active not recruiting 1 |
Follow Pathologic Stage IIIC Cutaneous Melanoma AJCC v8: new trials by email Literature Review of Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 trials Research Report on Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors Biopsy, Biospecimen Collection, Computed Tomography - Metastatic Malignant Solid Neoplasm, Metastatic Melanoma | Phase 1 | Recruiting | Anusha Kalbasi | 18 | 2025-10-07 | 2026-03-17 |
| Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma Biospecimen Collection, Cyclophosphamide, Echocardiography - Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma | Phase 2 | Completed | University of Kansas Medical Center | 11 | 2023-12-21 | 2026-04-30 |
| Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients Cyclophosphamide, Fludarabine, Lifileucel - Locally Advanced Melanoma, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Phase 1 | Active not recruiting | Richard Wu | 2 | 2022-07-01 | 2026-02-24 |
| Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer Neoantigen Peptide Vaccine, Nivolumab, Poly ICLC - Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 28 | 2022-06-09 | 2026-07-22 |
| Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors Medical Device Usage and Evaluation, Quality-of-Life Assessment, Survey Administration - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 | Active not recruiting | University of Southern California | 173 | 2021-11-24 | 2026-10-05 | |
| IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors Bevacizumab, Glutaminase-1 Inhibitor IACS-6274, Paclitaxel - Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 54 | 2021-09-30 | 2026-10-06 |
| Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma Ipilimumab, Nivolumab, Tocilizumab - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 35 | 2021-09-23 | 2026-09-16 |
| Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement Binimetinib, Conventional Surgery, Encorafenib - Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in Lymph Node | Phase 2 | Terminated | ECOG-ACRIN Cancer Research Group | 3 | 2021-09-22 | 2026-10-06 |
| Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma Dabrafenib mesylate, Hydroxychloroquine, Placebo Administration - Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Melanoma | Phase 2 | Terminated | ECOG-ACRIN Cancer Research Group | 5 | 2021-06-01 | 2026-10-06 |
| Bone Loss in Melanoma Survivors Receiving Immunotherapy Biospecimen Collection, Dual X-ray Absorptiometry - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Terminated | M.D. Anderson Cancer Center | 12 | 2021-05-10 | 2025-08-17 | |
| Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies Atezolizumab, Avelumab, Durvalumab - Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 19 | 2021-04-14 | 2026-04-30 |
| Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer Best Practice, Biospecimen Collection, Endoscopic Procedure - Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8 | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 800 | 2021-02-21 | 2026-07-15 |
| Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial Ipilimumab, Nivolumab, Patient Observation - Advanced Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8 | Phase 2 | Active not recruiting | ECOG-ACRIN Cancer Research Group | 150 | 2021-02-09 | 2026-09-15 |
| Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma Binimetinib, Nivolumab, Questionnaire Administration - Clinical Stage III Cutaneous Melanoma AJCC V8, Clinical Stage IV Cutaneous Melanoma AJCC V8 | Phase 2 | Terminated | Jonsson Comprehensive Cancer Center | 3 | 2020-12-03 | 2024-12-04 |
| Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma Dabrafenib, Spartalizumab, Therapeutic Conventional Surgery - Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Phase 2 | Terminated | M.D. Anderson Cancer Center | 4 | 2020-01-29 | 2024-10-30 |
| Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors Assessment, Biospecimen Collection, Quality-of-Life Assessment - Clinical Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8 | Active not recruiting | M.D. Anderson Cancer Center | 126 | 2019-12-05 | 2026-09-18 | |
| Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers Ipilimumab, Nivolumab, Prednisone - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 12 | 2019-11-08 | 2026-10-14 |
| CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma FACT Complex-targeting Curaxin CBL0137 - Advanced Cutaneous Melanoma of the Extremity, Advanced Sarcoma of the Extremity | Phase 1 | Terminated | Roswell Park Cancer Institute | 7 | 2019-07-01 | 2024-03-27 |
| Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta and Tyrosinase Related Protein 1 - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 1 | Terminated | Mayo Clinic | 12 | 2019-06-12 | 2026-01-28 |
| Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer Biospecimen Collection, Genetic Testing, Quality-of-Life Assessment - Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8 | Early Phase 1 | Completed | Mayo Clinic | 197 | 2019-06-06 | 2024-08-14 |
Showing 20 of 25. Sign in to see all of them.
Melanoma (14) · Lung Neoplasms (5) · Ovarian Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (4) · Neoplasm Metastasis (3) · Brain Neoplasms (2) · Carcinoma, Renal Cell (2) · Colorectal Neoplasms (2) · Fallopian Tube Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Urinary Bladder Neoplasms (2) · Urogenital Neoplasms (2) · Uveal Melanoma (2) · Adenocarcinoma of Lung (1) · Adenoma, Islet Cell (1)
Neoplasms (18) · Neoplasms by Site (18) · Neoplasms by Histologic Type (16) · Neoplasms, Germ Cell and Embryonal (15) · Neoplasms, Nerve Tissue (15) · Neuroectodermal Tumors (15) · Neuroendocrine Tumors (14) · Nevi and Melanomas (14) · Skin Diseases (14) · Skin Neoplasms (14) · Skin and Connective Tissue Diseases (14) · Female Urogenital Diseases (8) · Female Urogenital Diseases and Pregnancy Complications (8) · Urogenital Diseases (8) · Carcinoma (6)
Nivolumab (8) · CTLA-4 Antigen (5) · Cyclophosphamide (5) · Ipilimumab (5) · Disulfides (4) · Immunoglobulin G (4) · pembrolizumab (4) · Magnetic Resonance Spectroscopy (3) · Specimen Handling (3) · Biopsy (2) · Paclitaxel (2) · Prednisone (2) · Taxes (2) · atezolizumab (2) · binimetinib (2)
M.D. Anderson Cancer Center (8) · ECOG-ACRIN Cancer Research Group (3) · Mayo Clinic (3) · Roswell Park Cancer Institute (2) · Anusha Kalbasi (1) · Emory University (1) · Fred Hutchinson Cancer Center (1) · Jonsson Comprehensive Cancer Center (1) · National Cancer Institute (NCI) (1) · Richard Wu (1) · Rutgers, The State University of New Jersey (1) · University of Kansas Medical Center (1) · University of Southern California (1)
United States (25)
Allison Betof Warner, MD, PhD (1) · Antoni Ribas, MD, PhD (1) · Aung Naing, MD (1) · Evan J Lipson (1) · Geoffrey T Gibney (1) · Jewel Samadder, M.D. (1) · Joseph Skitzki (1) · Joshua Veatch (1) · Kimberly Miller, PhD (1) · Leslie A Fecher (1) · Maryam Buni (1) · Matthew S. Block, M.D., Ph.D. (1) · Michael Lowe, MD, MA (1) · Muhammad Umair Mushtaq (1) · Noha Abdelwahab Hassan (1)
PMID 32503950, PMID 33909232, PMID 34562230, PMID 34825282, PMID 34965890, PMID 35537412, PMID 36692933, PMID 36821617, PMID 37129197, PMID 37328287, PMID 38252910, PMID 38365756, PMID 39816915, PMID 39945382, PMID 40234093, PMID 40343719, PMID 40580957
U10CA180820 (3), P30CA014089 (1), P30CA016056 (1), P30CA138292 (1), P30CA168524 (1), R01CA164333 (1), R01CA221854 (1), R37CA256867 (1), UM1CA186691 (1)